

AUA2021 Summer School Instructional Course
 Evaluation and Management of Urinary Tract Bleeding: From Asymptomatic Microhematuria to
 Intractable Hemorrhagic Cystitis
 June 10, 2021

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Faculty Disclosures:

<u>Name</u>	<u>Company</u>	<u>Role</u>	<u>Financial</u>
Boorjian, Stephen A.	SUO-CTC Organized Clinical Trial Sponsored by FKD	Scientific Study or Trial	No
	Ferring	Consultant or Advisor	Yes
	ArTara	Consultant or Advisor	Yes
	FerGene	Consultant or Advisor	Yes
Barocas, Daniel Ari	progenics	Meeting Participant or Lecturer	Yes
Raman, Jay D.	American Kidney Stone Management	Investment Interest	Yes
	MDx Health	Scientific Study or Trial	No
	Pacific Edge Biotechnologies	Scientific Study or Trial	Yes
	Urogen Pharma	Scientific Study or Trial	No